Topical captopril: a promising treatment for secondary lymphedema

Transforming growth factor-beta 1 (TGF-β1)-mediated tissue fibrosis is an important regulator of lymphatic dysfunction in secondary lymphedema. However, TGF-β1 targeting can cause toxicity and autoimmune complications, limiting clinical utility. Angiotensin II (Ang II) modulates intracellular TGF-β1...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Translational research : the journal of laboratory and clinical medicine 2023-07, Vol.257, p.43-53
Hauptverfasser:	Brown, Stav, Nores, Gabriela D.G., Sarker, Ananta, Ly, Catherine, Li, Claire, Park, Hyeung Ju, Hespe, Geoffrey E., Gardenier, Jason, Kuonqui, Kevin, Campbell, Adana, Shin, Jinyeon, Kataru, Raghu P., Aras, Omer, Mehrara, Babak J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin II Angiotensin-Converting Enzyme Inhibitors - pharmacology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Animals Captopril - pharmacology Captopril - therapeutic use Fibrosis Lymphedema - drug therapy Lymphedema - etiology Mice Transforming Growth Factor beta1 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!